SOUTH PLAINFIELD, NJ--(Marketwired - July 31, 2013) - GENEWIZ, Inc.
, leading global genomics service provider, announced a collaboration with BeiGene, a biotechnology company focused on the discovery and development of innovative oncology treatment. The two companies will work together to accelerate cancer biomarker discovery, which will later aid drug target identification.
Headquartered in Beijing, BeiGene has established more than one hundred patient-derived primary tumor models in-house as part of their portfolio of oncology target therapies in early stage development. Utilizing OncoGxOne™ Discovery cancer panels, BeiGene will have the ability to identify and understand genetic variations in prevalent cancers throughout China and the Asia-Pacific region.
"Our collaboration with GENEWIZ and application of the OncoGxOne™ cancer panels will enable characterization of primary tumor models at the genetic level, with a focus on aberrations in cancer related genes," stated Dr. Lai Wang, Head of Discovery Biomarkers, BeiGene.
"Due to the unique ability to detect aberrations including gene fusions and copy number variance (CNV), using OncoGxOne™ Discovery cancer panels we have capabilities to identify novel mutations present in BeiGene's primary cancer tumor models," commented Dr. Guanghui Hu, Vice President of Translational Genomics. "Later, this invaluable information can be used for cancer diagnosis and treatment, which will have a direct impact on patient treatment and quality of life."
"We believe that this collaboration will strongly support our translational research and biomarker discovery," asserted Dr. Wang.
About GENEWIZ, Inc.
GENEWIZ, Inc. is a global contract research organization (CRO) specializing in genomic services, including DNA sequencing, gene synthesis, molecular biology, genomic, bioinformatics, and GxP/CLIA regulatory-compliant services. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions.
Headquartered in South Plainfield, NJ, GENEWIZ, Inc. is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; and Osaka, Japan.
BeiGene is a Chinese life sciences biotechnology company based in the Zhongguancun Life Science Park in Beijing that is focused on discovering and developing innovative oncology drugs that encompass novel small molecules and biologics. BeiGene is pursuing this through its own internal discovery laboratories in China and by in-licensing from pharmaceutical partners investigational therapeutics that address unmet medical needs for Chinese and Asian patients with cancer. BeiGene is also creating a robust biomarkers and bioinformatics platform to enable the identification of specific subsets of patient populations who will most likely benefit from the use of specific drugs or treatments. For more information, please visit www.beigene.com.